Journal article
Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors
Abstract
Angiotensin-converting enzyme 2 (ACE2), a newly discovered member of renin–angiotensin–aldosterone system, counterbalances the actions of angiotensin-converting enzyme. The objective of our study was to assess the association between rs2106809 polymorphism in ACE2 gene and the blood pressure response to ACE inhibitors in untreated hypertensive patients. After a 2-week, double-blind placebo run-in period, either benazepril or imidapril was …
Authors
Chen YY; Liu D; Zhang P; Zhong JC; Zhang CJ; Wu SL; Zhang YQ; Liu GZ; He M; Jin LJ
Journal
Journal of Human Hypertension, Vol. 30, No. 12, pp. 766–771
Publisher
Springer Nature
Publication Date
12 2016
DOI
10.1038/jhh.2016.24
ISSN
0950-9240
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdultAgedAngiotensin-Converting Enzyme 2Angiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsArterial PressureAsian PeopleBenzazepinesChinaDouble-Blind MethodGene FrequencyHeterozygoteHomozygoteHumansHypertensionImidazolidinesMiddle AgedPeptidyl-Dipeptidase APharmacogeneticsPharmacogenomic VariantsPhenotypePolymorphism, Single NucleotidePrecision MedicineProspective StudiesRenin-Angiotensin SystemSex FactorsTime FactorsTreatment Outcome